Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Adalimumab Biosimilars Near A Third

Executive Summary

Biosimilar adalimumab rivals to AbbVie’s Humira blockbuster continue to take market share in Germany, the latest market data demonstrates.

You may also be interested in...



Kabi Introduces Idacio Into Crowded German Adalimumab Market

Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.

Fresenius Nod In EU Adds To Crowded Adalimumab Market

Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.

German draft offers firms pro and cons

Positive measures including a drive to increase uptake of biosimilars are offset by more negative aspects, such as promoting pharmacy substitution of biologics and exposing cytostatic cancer therapies to tender processes, under draft medicines legislation unveiled by Germany’s ministry of health.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB139953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel